

TRANSGENOMIC INC  
Form 8-K  
April 14, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
April 9, 2010

TRANSGENOMIC, INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State of Incorporation)

000-30975  
(Commission File Number)

911789357  
(IRS Employer Identification  
Number)

12325 Emmet Street, Omaha, Nebraska  
(Address of principal executive offices)

68164  
(Zip Code)

(402) 452-5400

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02 Departure of Officer.

Effective as of April 9, 2010, Dr. Eric Kaldjian ceased to be the Chief Scientific Officer of the registrant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 14, 2010

TRANSGENOMIC, INC.

By: /s/ Debra A. Schneider  
Debra A. Schneider  
Chief Financial Officer